| 摘要 |
The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT<SUB>1</SUB>-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.
|
